Kezar Life Sciences, Inc. has entered into an asset purchase agreement with Enodia Therapeutics, acquiring its Sec61-based program assets for $1 million upfront and potential milestone payments totaling up to $127 million, enhancing Enodia's drug development capabilities.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.